DMPA can be used as i.m. (150 mg) or s.c. Injection (104 mg) every 3 months are given. The injection site is not massaged, as this would increase the absorption. Effective contraceptive hormone levels in serum are usually achieved 24 hours after injection and persist for at least 14 weeks, but the mirror can also be effective for up to 16 weeks. If the interval between injections is> 16 weeks to exclude pregnancy before next injection, a pregnancy test should be done. With DMPA can be started immediately (a “Quick Start Protocol”) when DMPA is administered within the first 5-7 days of the menstrual cycle. Is started outside of this period, should yet another method of contraception be used for 7 days for security additionally stops. DMPS may be added independently of any Breastfeeding also immediately after a spontaneous or induced abortions or immediately after childbirth.

Depot medroxyprogesterone acetate (DMPA) is a long-term effective, injectable formulation of medroxyprogesterone acetate in crystalline suspension. Pregnancy rates within the first year amount to 0.2% under ordinary conditions of use and are about 6% at normal application (i. E. After extension of the interval between injections). DMPA can be used as i.m. (150 mg) or s.c. Injection (104 mg) every 3 months are given. The injection site is not massaged, as this would increase the absorption. Effective contraceptive hormone levels in serum are usually achieved 24 hours after injection and persist for at least 14 weeks, but the mirror can also be effective for up to 16 weeks. If the interval between injections is> 16 weeks to exclude pregnancy before next injection, a pregnancy test should be done. With DMPA can be started immediately (a “Quick Start Protocol”) when DMPA is administered within the first 5-7 days of the menstrual cycle. Is started outside of this period, should yet another method of contraception be used for 7 days for security additionally stops. DMPS may be added independently of any Breastfeeding also immediately after a spontaneous or induced abortions or immediately after childbirth. The most common adverse side effect is an irregular vaginal bleeding. During the 3 months after the first DMPA injection about 30% of women have amenorrhea. Another 30% have spotting or (usually mild) irregular bleeding on> 11 days / month. Despite these bleeding abnormalities the result is usually no anemia. Over the further application, the bleeding decrease tendency. After 2 years, 70% get the DMPA of women have amenorrhea. Due to the long-lasting effect of DMPA ovulation by up to 18 months can be delayed to occur after the last injection. After ovulation, fertility is restored extremely fast. A weight gain of 1.5-4 kg during the first year of DMPA use is typical, and the women take after that to continue. Since it is assumed that the changes are due more to the appetite than on the metabolism, is usually advises women who want to use DMPA, reduce their caloric intake and increase their energy consumption. Headaches are a common reason to discontinue DMPA, the strength tends to decrease over time. Most women who receive DMPA, have no headache, and existing tension headaches and migraines usually do not worsen. Lightweight, reversible deterioration of glucose tolerance and lipid profile may occur. Although bone density may decrease with low estrogen levels, there is no evidence of an increased risk of fractures; a bone scan is not recommended in women who received DMPA. Adolescents and young women who use DMPA should like those who do not do this, 1500 mg Ca and 400 IU taking D / day of vitamin; if necessary, a vitamin supplement can be taken. Unlike oral combination preparations DMPA does not increase the risk of high blood pressure. Of progestogens is not believed to increase the risk of thromboembolism; however, there is evidence that the risk of thromboembolism can double with DMPA use. However, this relationship is not secured; DMPA is currently regarded as safe for women in whom estrogen is contraindicated. The risk for breast, ovarian and invasive cervical cancer is not increased apparently by DMPA. DMPA reduces the risk of endometrial cancer, pelvic inflammatory disease and iron deficiency anemia. There is evidence that DMPA reduces the number of painful crises in women with sickle cell anemia. For women with a seizure disorder DMPA may be an appropriate option for contraception. Other injections for contraception are available in other countries.

Health Life Media Team

Leave a Reply